EVX Ventures
EVX Ventures is a global venture capital firm established in 2015 and headquartered in Singapore. The firm focuses on building, incubating, and investing in early-stage biotechnology companies. It specializes in disruptive therapeutic platform technologies and novel therapeutic modalities, aiming to redefine future therapeutics. By investing in innovative global technologies, EVX Ventures seeks to advance the biotech industry and foster the development of transformative healthcare solutions.
2 past transactions
Carmine Therapeutics
Series A in 2022
Carmine Therapeutics, established in 2019 and headquartered in Singapore, specializes in gene therapy. It produces extracellular vesicles from red blood cells as a non-viral, re-dosable gene delivery vehicle, addressing challenges posed by traditional viral-based therapies such as immunogenicity, limited transgene capacity, and manufacturing complexities. The company focuses on developing next-generation gene therapies for hematology, oncology, and immunology.
Nuevocor
Series A in 2021
Nuevocor is a preclinical-stage biopharmaceutical company dedicated to developing gene therapy-based treatments aimed at restoring cardiac function in hearts affected by disease. The company specializes in addressing genetic cardiomyopathies, which are characterized by abnormal mechanobiology. By focusing on modulating mechanical force transduction, Nuevocor seeks to provide innovative solutions that enable healthcare professionals to improve cardiac function in patients suffering from these conditions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.